In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 

This content is currently on FREE ACCESS

 

Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor therapy.

Session Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management

Speaker Stefan Anker

Event : ESC Congress 2017

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure, Other
  • Session type : Satellite Symposium
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

This content is currently on FREE ACCESS

 

Other presentations from this session

Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management

  • ESC Congress 2017
  • Chronic Heart Failure, Other
  • Satellite Symposium
  • 27 August 2017
  • 12:45 - 13:45
session 2017 2017
5

Other presentations from this speaker

no speaker photo speaker

Stefan Anker

Charite Campus Virchow Clinic, Berlin (Germany)

117

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are